J&J Takes Ebola Vaccine Into Phase III
This article was originally published in Scrip
The Johnson & Johnson company, Janssen Pharmaceutical, has started a Phase III trial of its Ebola vaccine in Sierra Leone – pushing on with R&D for the candidate despite the initial Ebola crisis having calmed and other big players developing competing late-stage immunization options.
You may also be interested in...
How to make the most of the wealth of raw data in pharmaceutical R&D is an increasing challenge for the industry. The digital revolution is already having an impact in areas like clinical trials, and pharma is also starting to embrace new technologies in drug discovery.
Technology advancement has brought a wave of change in healthcare, with an increasing number of key pharma players now recognizing the potential of digital – particularly in clinical trials.
This week's roundup includes high-level appointments by Five Prime Therapeutics, Depomed and Gilead Sciences and board appointments by Verseon, Arix Bioscience, and Corbus Pharmaceuticals.